Universe · entity

Octagon Capital Advisors LP

Institutional manager (13F) · CIK 1839435
13F holdings · as of 2026-03-31 · top 29 · reported portfolio $904M
#IssuerValueShares
1DIANTHUS THERAPEUTICS INC$163M1,946,667
2COGENT BIOSCIENCES INC$90M2,350,000
3ABIVAX SA$75M677,000
4ALUMIS INC$62M2,830,700
5DEFINIUM THERAPEUTICS INC$46M2,440,000
6ARRIVENT BIOPHARMA INC$45M1,971,054
7TAYSHA GENE THERAPIES INC$40M8,859,911
8KYMERA THERAPEUTICS INC$35M425,000
9MIRUM PHARMACEUTICALS INC$31M338,900
10BIOAGE LABS INC$31M1,748,000
11CENTESSA PHARMACEUTICALS PLC$30M750,000
12KALVISTA PHARMACEUTICALS INC$29M1,450,000
13XENON PHARMACEUTICALS INC$28M490,000
14TERNS PHARMACEUTICALS INC$28M530,000
15OCULAR THERAPEUTIX INC$27M3,166,600
16PALISADE BIO INC$18M10,276,317
17TREVI THERAPEUTICS INC$18M1,485,000
18DISC MEDICINE INC$17M270,000
19AKTIS ONCOLOGY INC$17M960,847
20CONTEXT THERAPEUTICS INC$14M5,250,000
21PRECISION BIOSCIENCES INC$12M2,236,732
22DBV TECHNOLOGIES S A$12M574,200
23UNICYCIVE THERAPEUTICS INC$7M1,000,000
24BRIDGEBIO ONCOLOGY THERAPEUT$6M719,000
25LEXEO THERAPEUTICS INC$6M1,100,000
26PHARVARIS N V$5M165,000
27PERSPECTIVE THERAPEUTICS INC$3M791,555
28EVOMMUNE INC$3M143,472
29GOSSAMER BIO INC$3M7,750,000
All filings on EDGAR ↗

Source: sec_edgar_13f · public regulatory · retrieved 2026-06-29. Public SEC data; no contact information.